ACCPL — Accretion Pharmaceuticals Balance Sheet
0.000.00%
- IN₹1.12bn
- IN₹1.26bn
- IN₹336.65m
- 21
- 21
- 73
- 29
Annual balance sheet for Accretion Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IAS | IAS | IAS |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Short Term Investments | 3.75 | 0.364 | 0.916 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 45.7 | 66.6 | 68.5 |
| Total Inventory | |||
| Total Other Current Assets | |||
| Total Current Assets | 119 | 145 | 216 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 58.4 | 60.1 | 52.7 |
| Long Term Notes Receivable | |||
| Other Long Term Assets | |||
| Total Assets | 177 | 206 | 270 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 117 | 138 | 147 |
| Long Term Debt | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Deferred Income Tax | |||
| Total Other Liabilities | |||
| Total Liabilities | 147 | 167 | 217 |
| Common Stock | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 30.8 | 38.4 | 53.5 |
| Total Liabilities & Shareholders' Equity | 177 | 206 | 270 |
| Total Common Shares Outstanding |